Led by Dr. Susana Rives, the initiative aims to democratize access to these advanced treatments. The project will train centers in France, Italy, Belgium, and the Netherlands to produce the ARI-0001 therapy, originally developed at Hospital Clínic.
“"Industry invests more in those diseases that give them an economic return. Childhood cancer is a rare disease."
Hospital-based production costs approximately 90,000 euros per patient, significantly lower than the 320.000 euros charged by pharmaceutical companies. This public model speeds up delivery for children with relapsed acute lymphoblastic leukemia.
